FINWIRES · TerminalLIVE
FINWIRES

Clinuvel Pharmaceuticals Advances Nasdaq ADR Uplisting With US SEC Review Underway

作者

-- Clinuvel Pharmaceuticals (ASX:CUV) said it is working with the US Securities and Exchange Commission (SEC) on its draft registration statement as it advances plans to uplist its American depositary receipt (ADR) program on the Nasdaq stock market, according to a Tuesday filing with the Australian bourse.

The company received four rounds of US SEC comments and expects the review process to be completed before the end of the fiscal year, after which it plans to upgrade its ADR program to level two from level one and list on Nasdaq under the revised ticker "CUVL," per the filing.

The company stated that the uplisting is still subject to regulatory approval and Nasdaq requirements, and that its success and timing are not guaranteed, the filing added.

相关文章

Asia

Bio Port Korea第一季度恢复盈利

据韩国交易所周二发布的公告显示，韩国生物港公司（Bio Port Korea，KOSDAQ：188040）第一季度净利润达7.1亿韩元，较去年同期净亏损3400万韩元大幅扭亏为盈。 这家韩国保健食品公司的销售收入同比增长27%，从169亿韩元增至214亿韩元。 生物港公司的股价在近期的交易中上涨超过2%。

$KOSDAQ:188040
Asia

洋河啤酒2025年利润下降67%，营收下滑33%

江苏洋河啤酒（深圳证券交易所代码：002304）公布2025财年净利润为22.1亿元人民币，较上年同期的66.7亿元人民币下降67%。 根据周二提交给深圳证券交易所的文件，每股收益从4.4299元人民币降至1.4644元人民币。 该公司2025财年营收同比下降33%，从289亿元人民币降至192亿元人民币。

$SHE:002304
Asia

Resolution Minerals通过初步重力分离试验生产三氧化钨精矿，股价上涨4%。

据周二提交给澳大利亚证券交易所的文件显示，Resolution Minerals（ASX：RML）通过对钨复合样品进行初步重力分离试验，从约翰逊溪选矿厂的矿堆中分离出品位为52.3%的三氧化钨精矿。这些钨复合样品经化验，三氧化钨品位为1.85%。这些矿堆源自爱达荷州金门钨矿的历史开采。 对钨复合样品进行的重液分离初步试验也获得了52.3%的三氧化钨品位，回收率为75.5%。 该公司股价在周二的交易中上涨了4%。

$ASX:RML